AbCellera to Report Phase 2 VMS Data on August 10 — Key Catalyst for Lead Antibody
ABCL has more than doubled off its 52-week low of $2.745.
Summary
AbCellera announces top-line Phase 2 data for ABCL635 in vasomotor symptoms due to menopause will be released before market open on August 10, 2026, with a conference call to follow.
Key Events · Product Development and Regulatory · ABCL
-
Phase 2 Data Readout Scheduled
Top-line results from the Phase 2 trial of ABCL635 for moderate-to-severe VMS due to menopause will be released before market open on Monday, August 10, 2026.
-
Investor Call Set for August 10
Management will host a conference call at 4:30 a.m. PT / 7:30 a.m. ET on August 10 to discuss the data.
-
First Clinical Catalyst for GPCR Platform
ABCL635 is the first program from AbCellera's GPCR and ion channel platform to reach Phase 2 data, representing a key validation point for the company's internal pipeline.
-
Large Market Opportunity
ABCL635 targets the non-hormonal treatment of menopausal hot flashes, a large and underserved market, with a novel mechanism (NK3R antagonism).
Analysis · ABCL · Life Sciences
On Monday, August 10, AbCellera will release top-line Phase 2 data for ABCL635, its lead antibody targeting menopausal hot flashes. This marks the first clinical readout from the company's GPCR and ion channel platform and represents a major binary event for the stock. Positive data would validate the platform and unlock a large market opportunity, while failure would be a significant setback. The company has been building momentum with recent high-profile collaborations with Jazz and Vertex, but ABCL635 is the first wholly-owned program to reach this stage.
How filings like this one have moved
In the 30 days to Sep 22, 2026, 34.8% of the 1044 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABCL was trading at $7.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $2.75 to $8.44. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.